Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia

Conclusion Abrupt dabigatran discontinuation without an alternative oral anticoagulant increases the risk of thromboembolic events. As adverse drug events and renal impairment contribute substantially to the premature discontinuation of dabigatran, it is important to identify and monitor patients at risk to reduce dabigatran discontinuation rate especially during the first six months of dabigatran therapy.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research